Juliana Woda, PhD is Vice President of Therapeutics Development and Director of the Therapeutics Development Center (TDC) and manages the portfolio of scholar projects that are supported by the Harrington Discovery Institute.
Julie is a skilled biotechnology leader with experience leading cross functional teams in drug discovery and expertise in operational, scientific and business functions. At Harrington Discovery Institute, her portfolio management role is critical for ensuring that the Harrington Innovator, ADDF-Harrington and Oxford-Harrington scholar drug discovery projects have access to support and guidance that will help translate their ideas to the clinic and to patients. A key component of that support is the TDC Advisors, which Julie directs. Members of the TDC panel bring pharma expertise and know-how to the portfolio projects with a view to accelerating the development of new therapies.
Julie obtained her PhD in Cell and Developmental Biology at Harvard University and did her postdoctoral training at Massachusetts General Hospital in the Center for Genomic Medicine. During her more than 20 years in the drug discovery field, she has been part of project teams that yielded multiple INDs and clinical trials, licenses to pharma and startups. She has a combination of experience in industry and not-for-profit settings on both the scientific and business side.
Prior to joining Harrington Discovery Institute, Julie served as Senior Director and Domain Lead of Therapeutics and Diagnostics at Cleveland Clinic Innovations, as Senior Director at BioMotiv, cofounder of Clarametyx Biosciences, and Director of Translational Research at Juventas.